Hepatitis B: An assessment of current and future treatment options

D. D. Douglas, D. J. Post

Research output: Contribution to journalArticle

Abstract

Despite dramatic reductions in the incidence of new hepatitis B virus (HBV) infections in the past decade, about 1.25 million Americans have chronic HBV infection, putting them at increased risk for developing complications of chronic liver disease and hepatocellular carcinoma. Candidates for antiviral therapy include individuals with chronic active (replicative) HBV infection. Currently available options for treating chronic HBV infection are interferon alfa-2b and the oral nucleoside analog lamivudine. While interferon alfa can be effective in terminating viral replication and eradicating the carrier state in patients positive for HBeAg, it does not yield a sustained response in 60% to 70% of patients and is associated with significant adverse effects. Lamivudine is a potent suppressor of HBV replication and is effective initially in the large majority of treatment-naïve patients. However, prolonged lamivudine therapy is associated with frequent development of viral resistance. Hepatitis B immune globulin products are available for passive immunization in individuals exposed to HBV and are increasingly used as immunoprophylaxis against recurrence of HBV after liver transplantation. This article reviews and assesses current evidence on the use of these agents as well as five experimental therapies for chronic HBV infection.

Original languageEnglish (US)
Pages (from-to)708-724
Number of pages17
JournalFormulary
Volume36
Issue number10
StatePublished - 2001

Fingerprint

Hepatitis B
Hepatitis B virus
Virus Diseases
Lamivudine
Chronic Hepatitis B
interferon alfa-2b
Therapeutics
Carrier State
Investigational Therapies
Passive Immunization
Hepatitis B e Antigens
Chronic Hepatitis
Virus Replication
Nucleosides
Interferon-alpha
Liver Transplantation
Antiviral Agents
Immunoglobulins
Liver Diseases
Hepatocellular Carcinoma

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Douglas, D. D., & Post, D. J. (2001). Hepatitis B: An assessment of current and future treatment options. Formulary, 36(10), 708-724.

Hepatitis B : An assessment of current and future treatment options. / Douglas, D. D.; Post, D. J.

In: Formulary, Vol. 36, No. 10, 2001, p. 708-724.

Research output: Contribution to journalArticle

Douglas, DD & Post, DJ 2001, 'Hepatitis B: An assessment of current and future treatment options', Formulary, vol. 36, no. 10, pp. 708-724.
Douglas, D. D. ; Post, D. J. / Hepatitis B : An assessment of current and future treatment options. In: Formulary. 2001 ; Vol. 36, No. 10. pp. 708-724.
@article{fa879969fde842998c381e8fa774540a,
title = "Hepatitis B: An assessment of current and future treatment options",
abstract = "Despite dramatic reductions in the incidence of new hepatitis B virus (HBV) infections in the past decade, about 1.25 million Americans have chronic HBV infection, putting them at increased risk for developing complications of chronic liver disease and hepatocellular carcinoma. Candidates for antiviral therapy include individuals with chronic active (replicative) HBV infection. Currently available options for treating chronic HBV infection are interferon alfa-2b and the oral nucleoside analog lamivudine. While interferon alfa can be effective in terminating viral replication and eradicating the carrier state in patients positive for HBeAg, it does not yield a sustained response in 60{\%} to 70{\%} of patients and is associated with significant adverse effects. Lamivudine is a potent suppressor of HBV replication and is effective initially in the large majority of treatment-na{\"i}ve patients. However, prolonged lamivudine therapy is associated with frequent development of viral resistance. Hepatitis B immune globulin products are available for passive immunization in individuals exposed to HBV and are increasingly used as immunoprophylaxis against recurrence of HBV after liver transplantation. This article reviews and assesses current evidence on the use of these agents as well as five experimental therapies for chronic HBV infection.",
author = "Douglas, {D. D.} and Post, {D. J.}",
year = "2001",
language = "English (US)",
volume = "36",
pages = "708--724",
journal = "Formulary",
issn = "1082-801X",
publisher = "Advanstar Communications",
number = "10",

}

TY - JOUR

T1 - Hepatitis B

T2 - An assessment of current and future treatment options

AU - Douglas, D. D.

AU - Post, D. J.

PY - 2001

Y1 - 2001

N2 - Despite dramatic reductions in the incidence of new hepatitis B virus (HBV) infections in the past decade, about 1.25 million Americans have chronic HBV infection, putting them at increased risk for developing complications of chronic liver disease and hepatocellular carcinoma. Candidates for antiviral therapy include individuals with chronic active (replicative) HBV infection. Currently available options for treating chronic HBV infection are interferon alfa-2b and the oral nucleoside analog lamivudine. While interferon alfa can be effective in terminating viral replication and eradicating the carrier state in patients positive for HBeAg, it does not yield a sustained response in 60% to 70% of patients and is associated with significant adverse effects. Lamivudine is a potent suppressor of HBV replication and is effective initially in the large majority of treatment-naïve patients. However, prolonged lamivudine therapy is associated with frequent development of viral resistance. Hepatitis B immune globulin products are available for passive immunization in individuals exposed to HBV and are increasingly used as immunoprophylaxis against recurrence of HBV after liver transplantation. This article reviews and assesses current evidence on the use of these agents as well as five experimental therapies for chronic HBV infection.

AB - Despite dramatic reductions in the incidence of new hepatitis B virus (HBV) infections in the past decade, about 1.25 million Americans have chronic HBV infection, putting them at increased risk for developing complications of chronic liver disease and hepatocellular carcinoma. Candidates for antiviral therapy include individuals with chronic active (replicative) HBV infection. Currently available options for treating chronic HBV infection are interferon alfa-2b and the oral nucleoside analog lamivudine. While interferon alfa can be effective in terminating viral replication and eradicating the carrier state in patients positive for HBeAg, it does not yield a sustained response in 60% to 70% of patients and is associated with significant adverse effects. Lamivudine is a potent suppressor of HBV replication and is effective initially in the large majority of treatment-naïve patients. However, prolonged lamivudine therapy is associated with frequent development of viral resistance. Hepatitis B immune globulin products are available for passive immunization in individuals exposed to HBV and are increasingly used as immunoprophylaxis against recurrence of HBV after liver transplantation. This article reviews and assesses current evidence on the use of these agents as well as five experimental therapies for chronic HBV infection.

UR - http://www.scopus.com/inward/record.url?scp=0034770757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034770757&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034770757

VL - 36

SP - 708

EP - 724

JO - Formulary

JF - Formulary

SN - 1082-801X

IS - 10

ER -